Search Results - bacillus

5 Results

Sort By:

Stable, Early-stage Biomarker for Diagnosis of Bacillus anthracis Infection and Anthrax Vaccine Development

This invention comprises monoclonal antibodies, proteins, and related nucleic acid coding sequences that identify all or part of the antigenic anthrose oligosaccharide of Bacillus anthracis, the causative agent of anthrax toxicity in humans. It is imperative to identify virulent B. anthracis with speed and specificity, however there presently is substantial...

Published: 4/8/2024 | Inventor(s): Conrad Quinn, Geert-Jan Boons, Russell Carlson, Elke Saile

Keywords(s): Anthracis, ANTHROSE, antibodies, Bacillus, CDC Docket Import, CDC Docket Import NP, Cell, DA3XXX, DAXXXX, DB3XXX, DBXXXX, DEXXXX, DXXXXX, Hybridoma, Lines, monoclonal, Recognizing, SACCHARIDE, VBXXXX, VJXXXX, VOXXXX, WAXXXX, WBXXXX, WFXXXX, WIXXXX, WMXXXX, XAXXXX, XCXXXX, XEXXXX, XHXXXX, YBXXXX, YCXXXX

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease, Application > Consumer Products, Application > Occupational Safety and Health, Application > Therapeutics, ResearchProducts > Antibodies, TherapeuticArea > Immunology, Application > Research Materials, Application > Diagnostics, ResearchProducts > Research Equipment

Novel Epitopes of Bacillus anthracis Lethal Factor for Development of Diagnostics and Therapeutics

CDC researchers have characterized epitopes of Bacillus anthracis Lethal Factor (LF), a critical component of the B. anthracis lethal toxin. These epitopes may allow for development of therapeutics for the treatment or prevention of B. anthracis infection. They may also allow screening for B. anthracis LF in a sample and development of a peptide anthrax...

Published: 7/25/2024 | Inventor(s): Dennis Bagarozzi, Anne Boyer, Conrad Quinn, Jason Goldstein

Keywords(s): Activiating, Activity, Anthracis, Anthrax, AnthraxToxins, Bacillus, Biodefense, biosecurity, bioterrorism, Bioterrorist, CDC Docket Import, CDC Docket Import CDC Prosecuting, DA3XXX, DA5XXX, DAXXXX, DB3XXX, DB5XXX, DBXXXX, DC4XXX, DCXXXX, DXXXXX, Epitope, factor, INFECTIOUS, Lethal, MONITOR, MONITORING, Neutralize, Neutralizing, Region, REGULATING, SCREEN, screening, SERODIAGNOSIS, SERODIAGNOSTIC, Serologic, SEROLOGICAL, therapeutic, Therapeutic/Diagnostic, THERAPY, toxin, TOXIN-BINDING, Vaccine, VBXXXX, VETERINARY, Via, VJXXXX, VOXXXX, WAXXXX, WBXXXX, WFXXXX, WJXXXX, WKXXXX, WMXXXX, XAXXXX, XCXXXX, XHXXXX, YAXXXX, YBXXXX, Zoo, Zoonotic

Category(s): Collaboration Sought > Licensing, Application > Vaccines, Application > Occupational Safety and Health, TherapeuticArea > Infectious Disease, Application > Consumer Products, Application > Therapeutics, ResearchProducts > Research Equipment, TherapeuticArea > Immunology, Application > Research Materials, ResearchProducts > Antibodies, Application > Diagnostics

Linear Epitopes of Anthrax Toxin Protective Antigen for Development of a Peptide Vaccine

Bacillus anthracis is a gram-positive, spore-forming bacteria that causes anthrax infection in humans. CDC inventors have identified epitope sequences of B. anthracis protective antigen (PA) that may be useful for development of peptide-based anthrax vaccines. This invention also relates to methods for determining whether post-vaccination protection...

Published: 7/25/2024 | Inventor(s): Conrad Quinn, Jan Pohl, Pavel Svoboda, Shannon Dalton, Jarad Schiffer, Stephen Soroka, Vera Semenova

Keywords(s): Anthrax, ANTIGEN, Bacillus, biosecurity, Bioterrism, Bio-terrorism, Bioterrorist, BioWarfare, CDC Docket Import, CDC Docket Import CDC Prosecuting, DC1XXX, DC4XXX, DCXXXX, Development, DXXXXX, Epitopes, LINEAR, OID-NCIRD-DBD, PA, Peptide, Protection, Protective, toxin, Vaccine

Category(s): Collaboration Sought > Licensing, Application > Vaccines, TherapeuticArea > Infectious Disease

Protease Deficient Bacillus anthracis with Improved Recombinant Protein Yield Capabilities

Species of Bacillus, such as Bacillus anthracis, Bacillus cereus, and Bacillus subtilis, are attractive microorganisms for recombinant protein production in view of their fast growth rate, high yield, and ability to secrete produced products directly into the medium. Bacillus anthracis is also attractive in view of its ability to produce anthrax toxin...

Published: 7/25/2024 | Inventor(s): Stephen Leppla, Andrei Pomerantsev

Keywords(s): Anthracis, Anthrax, ATCC, Bacillus, Bacterial, BH460, DB3XXX, DBXXXX, DC4XXX, DC6XXX, DCXXXX, DDXXXX, DEXXXX, DXXXXX, HOST, Improved, production, proteins, toxin, vaccines

Category(s): Collaboration Sought > Collaboration, Application > Vaccines, Application > Therapeutics, Application > Research Materials, TherapeuticArea > Infectious Disease

Monoclonal Antibodies That React With the Capsule of Bacillus anthracis

Bacillus anthracis is the causative agent of anthrax and is surrounded by a polypeptide capsule of poly-gamma-D-glutamic acid (gammaDPGA). gammaDPGA is poorly immunogenic and has antiphagocytic properties. The bacterial capsule is essential for virulence. Antibodies to the capsule have been shown to enhance phagocytosis and killing of encapsulated...

Published: 7/25/2024 | Inventor(s): Robert Purcell, Rachel Schneerson, Joanna Kubler-kielb, Lily Zhongdong Dai, Zhaochun Chen

Keywords(s): Anthracis, Anthrax, antibodies, Autoimmune polyendocrinopathy syndrome, type 1, Bacillus, Capsule, chimeric, Chimpanzee/Human, DA3XXX, DAXXXX, DB3XXX, DBXXXX, DC4XXX, DCXXXX, DDXXXX, DXXXXX, KILL, monoclonal, Opsonophagocytosis, ORGANISM, Patent Category - Biotechnology, PGA 1, PGA 2, REACT, Schmidt syndrome, That

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Research Materials, Application > Diagnostics, Application > Vaccines, Application > Therapeutics, TherapeuticArea > Infectious Disease